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Purpose: The aim of this study was to characterize the arylsulfatase I (ARSI) gene that has been shown to be preferentially
expressed in the human retinal pigment epithelium cell line ARPE-19 and to propose it as a candidate gene responsible
for inherited eye diseases such as retinitis pigmentosa (RP).
Methods: Full-length cDNA clones encoding ARSI, arylsulfatase A (ARSA), and sulfatase modifying factor 1 (SUMF1)
were isolated from ARPE-19 cDNA libraries constructed using the vector-capping method. The expression vectors for
their FLAG-tagged proteins were transfected into ARPE-19 cells, and the expression products were characterized by
western blot analysis and arylsulfatase assay. The entire region of the ARSI gene locus was sequenced using the genomic
DNA samples of 68 RP patients.
Results: Transiently produced ARSI-FLAG was localized to the endoplasmic reticulum and was detected in the cellular
fraction and the medium. When ARSI-FLAG and SUMF1-FLAG were coexpressed, the conditioned medium of the
transfected cells showed arylsulfatase activity at a range of neutral pH. No mutation was found in the ARSI gene locus of
the RP patients examined.
Conclusions: ARSI may be a secreted sulfatase and may function in the extracellular space. Although ARSI may not be
a causative gene for lysosomal storage diseases, preferentially expressed in the eye, ARSI would be a candidate gene
causing inherited eye diseases for future mutation screening.
Sulfatases  represent  a  large  enzyme  family  that
hydrolyzes sulfate esters and sulfamates [1]. The majority of
human sulfatases reside in lysosomes and are responsible for
the degradation of sulfated carbohydrates. As their enzymatic
activities have been measured using small aryl substrates such
as p-nitrophenol sulfate or 4-methylumbelliferyl sulfate (4-
MUS),  these  sulfatases  are  named  arylsulfatase  (ARS).
Alignment of the amino acid sequences of ARSs has shown
the presence of two conserved regions at their N-terminal end.
Signature  sequence  I  contains  a  cysteine  residue  that  is
converted into the catalytically active formylglycine (FGly)
residue [2] by post-translational modification with sulfatase
modifying  factor  1  (SUMF1)  [3,4]  in  the  endoplasmic
reticulum (ER). The search analysis for sulfatase genes across
the human genome using the above conserved sequences has
revealed a total of 17 sulfatase genes, including 4 novel genes,
arylsulfatase H (ARSH), arylsulfatase I (ARSI), arylsulfatase
J (ARSJ), and arylsulfatase K (ARSK) [5]. ARSI and ARSJ are
regarded as ARSB paralogs. Recently, ARSI and ARSJ cDNAs
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have been cloned and expressed in HeLa cells, but no ARS
activity has been detected [6].
Mutations or deficiencies of the ARS genes have been
found  to  cause  lysosomal  storage  diseases  such  as
mucopolysaccharidoses  (MPS)  and  metachromatic
leukodystrophy [7]. Patients with these diseases often suffer
from  retinal  degeneration  similar  to  that  seen  in  retinitis
pigmentosa  (RP)  [8-13].  The  lysosomal  storage  in  retinal
pigment  epithelium  (RPE)  cells  is  suspected  to  cause  the
degeneration of photoreceptor cells [11].
RP  is  a  set  of  hereditary  retinal  diseases  caused  by
degeneration  of  photoreceptor  cells.  More  than  45  genes
responsible  for  RP  have  been  identified  and  account  for
approximately 60% of RP patients in the United States [14].
However, many of the responsible genes remain unidentified.
To identify novel candidate genes causing RP, we have been
searching for genes preferentially expressed in human retina-
derived cell lines [15,16]. During this search, we found that
ARSI is preferentially expressed in RPE cell line ARPE-19.
We thought that ARSI might be a possible candidate for an
RP-responsible gene because mutations of ARSs are known
to cause MPS accompanied by symptoms of RP. In this paper,
we describe the cloning of full-length cDNAs of ARS-related
genes,  the  transient  expression  of  ARSI  cDNA  and  the
detection of ARS activity of its product. Further, we report the
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482results  of  mutation  screening  of  the  ARSI  gene  locus  in
Japanese RP patients.
METHODS
cDNA  cloning:  The  cloning  of  full-length  cDNAs  was
performed using a full-length cDNA collection consisting of
93,504 clones randomly isolated from the cDNA libraries that
had been constructed from total RNA of ARPE-19 cells using
a vector-capping method as described in the previous papers
[15,16]. Full-length cDNA encoding ARSI was identified by
the 5′-end single-pass sequencing of 24,000 clones. Those for
ARSA  and  SUMF1  were  obtained  by  polymerase  chain
reaction  (PCR)-based  screening  of  the  remaining  69,504
clones. Full sequencing of the obtained clones was performed
using a primer walking method, and the determined sequences
were registered to DDBJ/GenBank/EMBL under accession
numbers,  AB448735  (ARSI),  AB448736  (ARSA),  and
AB448737 (SUMF1).
Sequencing:  Sequencing  reactions  were  performed  with  a
BigDye®  Terminator  Cycle  Sequencing  Kit  (Applied
Biosystems, Foster City, CA). The M13 universal forward
primer  was  used  for  the  5′-end  single-pass  sequencing.
Primers used for genome sequencing are listed in Table 1.
Sequencing  reaction  products  were  run  on  an  automated
capillary  sequencer  (Applied  Biosystems  3130xl  Genetic
Analyzer, Applied Biosystems).
Cell  culture:  Human  retinal  pigment  epithelium  cell  line
ARPE-19, human retinoblastoma cell line Y79, and human
embryonal carcinoma cell line NTERA-2 cl.D1 (NT2/D1)
were  obtained  from  American  Type  Culture  Collection
(Manassas, VA). Human fibrosarcoma cell line HT-1080 and
TABLE 1. PRIMERS USED FOR SEQUENCING THE ARYLSULFATASE I GENE LOCUS.
Primer Position Sequence (5′->3′)
Forward
SF01 -232 CCCGGTTGGACTAGGAAATGATGGGCTT
SF02 229 GGAAGAGGGGAGTCAGAGGATG
SF03 710 CCCCAGCCTCCCCACATCATCT
SF04 1140 CATCTGGTCATCCCTTTGTTAG
SF05 1588 GGCGAGGCAGCAGGATTACAGG
SF06 2041 GGGGTGGTGGTGCAGGTTAGTG
SF07 2393 TTGGTGACTCTTAGCTGGC
SF08 2887 CTGGAGGTGAGAAAAAGGTGTGGG
SF09 3313 TCTGTTCCTGACCACCGAGCGA
SF10 3745 TGCTCTAGGCCCCAGTGCAAGTTA
SF11 4143 CCAGTGATTTTGAGGATTCGATGAG
SF12 4525 CACCTTCCTGGGCTCGCTCACG
SF13 4981 TTATTGGGAAGGTGGCGTGCGG
SF14 5377 GTGGAACCTGGAACGAATGGCC
SF15 5836 CAGGGAGTTGGAGGGTGTAGAG
Reverse
SR01 250 CATCCTCTGACTCCCCTCTTCC
SR02 731 AGATGATGTGGGGAGGCTGGGG
SR03 907 CTTGAGCCACGCCTACCTGCC
SR04 1161 CTAACAAAGGGATGACCAGATG
SR05 1609 CCTGTAATCCTGCTGCCTCGCC
SR06 2062 CACTAACCTGCACCACCACCCC
SR07 2472 CAACTGGGCCGGTCTTCATAG
SR08 2910 CCCACACCTTTTTCTCACCTCCAG
SR09 3334 TCGCTCGGTGGTCAGGAACAGA
SR10 3768 TAACTTGCACTGGGGCCTAGAGCA
SR11 4167 CTCATCGAATCCTCAAAATCACTGG
SR12 4546 CGTGAGCGAGCCCAGGAAGGTG
SR13 5002 CCGCACGCCACCTTCCCAATAA
SR14 5398 GGCCATTCGTTCCAGGTTCCAC
SR15 5857 CTCTACACCCTCCAACTCCCTG
SR16 6262 TCAACCCCCCCGACCCCTGCCC
SR17 6442 GTCCTGGTACTGGTTTGGGGGCTCTTCACAG
Position 1 corresponds to the nucleotide A of the initiation codon of the ARSI gene.
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483human adenocarcinoma cell line HeLa S3 (sc) were obtained
from  the  Japanese  Collection  of  Research  Bioresources
(Osaka, Japan). The culture medium was a 1:1 mixture of
Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s
F-12  medium  (Invitrogen,  Carlsbad,  CA)  containing  10%
fetal bovine serum (FBS, JRH Biosciences, Lenexa, KS) for
ARPE-19, and RPMI1640 medium (Invitrogen) containing
20%  FBS  for  Y79.  The  other  cell  lines  were  cultured  in
DMEM with 4.5 g/l of glucose (Sigma Aldrich, St. Louis,
MO)  containing  10%  FBS,  and  for  HT-1080  further
supplemented  with  10  mM  HEPES  and  0.1  mM  MEM
nonessential amino acids (Sigma Aldrich). The incubation
was performed at 37 °C in a humidified atmosphere of 5%
CO2 and 95% air (10% CO2 and 90% air for NT2/D1).
Reverse transcription polymerase chain reaction: Total RNA
was isolated using Isogen® (Nippon Gene, Tokyo, Japan). The
first-strand cDNA was synthesized from total RNA using
oligo  (dT)30  as  a  primer  with  SuperScriptTM  III  reverse
transcriptase (Invitrogen), and then purified by a Wizard®
PCR preps DNA Purification System (Promega, Madison,
WI). The cDNA sample equivalent to 100 ng of total RNA
was amplified with TaKaRa Ex TaqTM polymerase (Takara
Bio Inc., Shiga, Japan). Table 2 shows the primers used for
PCR amplification of each cDNA. The PCR conditions were
as follows: initial denaturation at 96 °C for 2 min, 40 cycles
of heating at 96 °C (98 °C for ARSI) for 30 s, annealing at
60 °C (63 °C for ARSI) for 30 s, and extension at 72 °C for 2
min (4 min for ARSI), followed by final extension at 72 °C for
10 min.
In  silico  expression  profile:  The  counts  of  the  expressed
sequence  tag  (EST)  obtained  from  various  tissues  were
retrieved from the UniGene website. The UniGene cluster
number  is  Hs.591252  for  ARSI,  Hs.88251  for  ARSA,  Hs.
149103 for ARSB, and Hs.350475 for SUMF1.
Construction  of  expression  vectors:  FLAG-epitope-tagged
expression  vectors  for  ARSI,  ARSA,  and  SUMF1  (ARSI-
FLAG, ARSA-FLAG, and SUMF1-FLAG) and a myc-tagged
vector  for  SUMF1  (SUMF1-myc)  were  constructed.  The
coding region of each cDNA was amplified using the primers
shown in Table 3 and was cloned into pFLAG-CMV-5 (Sigma
Aldrich)  or  pcDNA3.1/myc-His  (Invitrogen).  ARSICΔ46
lacks the 46 C-terminal amino acids of ARSI. By replacing
the signal peptide of ARSI with that of SUMF1, S1ARSI-myc
was constructed, and the amplified S1ARSICΔ46 fragment
was  then  subcloned  into  pFLAG-CMV-5  to  construct  the
expression vector of S1ARSICΔ46-FLAG.
Site-directed mutagenesis: A single amino acid substitution
of the ARSI gene was performed using the QuikChange® II
Site-Directed  Mutagenesis  Kit  (Stratagene,  La  Jolla,  CA)
according  to  the  manufacturer’s  protocol.  A  cysteine  at
position 93, a putative active site of ARSI, was replaced by a
serine. The mutation was introduced into ARSI-FLAG using
an oligonucleotide, 5′-CAT CCA GCC CAT CTC CAC GCC
TTC GC-3′, to construct an expression vector of ARSI-C93S-
FLAG.
Transfection:  Transfection  of  the  expression  vector  into
ARPE-19  cells  was  performed  using  the  Amaxa
Nucleofector®  system  (Amaxa  Inc.,  Gaithersburg,  MD)
according  to  the  manufacturer’s  directions.  The  cultured
ARPE-19  cells  were  trypsinized  and  harvested  by
centrifugation.  The  cell  pellet  was  resuspended  in
Nucleofector® Solution R to a final concentration of 1.5x106
cells/100  μl.  When  the  multiple  expression  vectors  were
coexpressed, the total amount of the introduced plasmid DNA
vectors was adjusted to be constant by adding a control vector
pFLAG-CMV-5a. The cell suspension was mixed with a total
amount of 6–10 μg of plasmid DNA, and electroporation was
then performed using the program P-20 of the Nucleofector®
device (Amaxa). The transfected cells were seeded in the
growth medium containing FBS and cultured for 24–72 h. For
the enzymatic assay, the medium was replaced with serum-
free medium 2 h after transfection.
Immunofluorescence: The transfected cells were grown on a
culture  slide  for  24  h.  The  cells  were  fixed  in  4%
paraformaldehyde for 15 min and then permeabilized with
methanol.  FLAG-tagged  protein  was  detected  by
immunostaining  with  20  μg/ml  primary  anti-FLAG  M2
antibody (Sigma Aldrich) and 1:200 secondary anti-mouse
IgG Alexa Fluor® 568 antibody (Molecular Probes, Eugene,
OR). Endogenous lysosomal and ER proteins were detected
with 1:100 primary anti-cathepsin D (H-75) and 1:100 anti-
PDI (protein disulfide isomerase, H-160) antibodies (Santa
TABLE 2. PRIMERS FOR REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION AND PRODUCT SIZES.
Gene Primer name Sequence (5′-3′) Product size (bp)
EEF1A1 107fw CGTAGATTCGGGCAAGTCCACCAC 1265
1371rv CACCCACCGCAACTGTCTGTCTCA
ARSA 807fw TCTAGGCATCCCGTACTC 1047
1853rv CAGCCAGGATGACAGCAGA
ARSI 187fw AGGAGAGAGAAATTAGGAGGCGGG 2800
2986rv GTACTGGTTTGGGGGCTCTTCACA
SUMF1 232fw ATACTCGCGGGAGGCTAA 1324
1555rv ACACCCAGAGGTCATGCT
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484Cruz  Biotechnology,  Santa  Cruz,  CA),  respectively,  and
1:200 secondary anti-rabbit IgG Alexa Fluor® 488 antibody
(Molecular Probes). The cells were incubated with primary
antibodies at 4 °C overnight and secondary antibodies at room
temperature for 4 h in the dark after blocking with 1% BSA
(Sigma Aldrich) in PBS for 1 h. The cells were mounted in
ProLong® Gold antifade reagent (Invitrogen) and observed
using  a  Bio-Rad  MRC-1024  confocal  laser  microscope
(BioRad, Hercules, CA) .
Preparation  of  expression  products:  The  ARPE-19  cells
transfected with the FLAG-tagged expression vectors were
seeded in 6 cm dishes and incubated at 37 °C for 24–72 h. The
medium  was  concentrated  on  an  Ultrafree  filter  unit
(5000NMWL; Millipore, Bedford, MA) and then dissolved in
100 μl of 50 mM Tris-HCl buffer (pH 7.4) containing 0.5%
TritonX-100  and  1  mM  phenylmethylsulfonyl  fluoride
(Sigma  Aldrich).  Trichloroacetic  acid  (TCA)  precipitation
was performed by mixing the medium with an equal volume
of a 20% (w/v) TCA/acetone solution and was incubated at
−20 °C for 3 h. The precipitate was collected by centrifugation
and then washed three times with cold acetone. The cells were
disrupted by sonication in 50 mM Tris-HCl buffer (pH 7.4)
containing 1% Tween-20 and 1 mM phenylmethylsulfonyl
fluoride, and were agitated at 4 °C overnight. The soluble
cellular  extract  was  separated  from  the  insoluble  cellular
fraction by centrifugation. The protein concentration of the
cellular extract was determined using a DC Protein Assay kit
(Bio-Rad).
Western  blot  analysis:  The  soluble  cellular  extract,  the
insoluble cellular fraction, the concentrated medium, and the
TCA precipitate were treated with an SDS–PAGE sample
buffer that contained 50 mM Tris-HCl, pH 6.8, 2% SDS, 6%
2-mercaptoethanol, and 10% glycerol. The mixture was then
boiled for 10 min. The samples were electrophoresed on a 10%
polyacrylamide gel in a glycine-SDS buffer and transferred
onto  Immun-Blot  PVDF  membranes  (Bio-Rad).  The
membranes were blocked with 1% (w/v) nonfat dried milk
(Roche Applied Science, Indianapolis, IN) in maleic acid
buffer (pH 7.5) for 1 h at room temperature, and then exposed
to  10  μg/ml  primary  anti-FLAG  BioM2  antibody  (Sigma
Aldrich) for 1 h, followed by 1:1,000 alkaline phosphatase-
linked anti-biotin antibody (Vector Laboratories, Burlingame,
CA)  for  30  min.  The  bands  were  visualized  by  nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate
chromogen (Roche Applied Science). The production level
was estimated by measuring the density of the band using a
bio-imaging  system  (ChemiStage  CC-16,  Kurabo,  Osaka,
Japan).
Arylsulfatase assay: The ARS activity of the cellular extract
and medium was determined by incubating 20 μl of the sample
solution with 80 μl of 6.25 mM 4-MUS (Sigma Aldrich) as a
substrate and 0.125 M sodium acetate (pH 5.0–6.0) or Tris-
HCl buffer (pH 6.8–9.0) according to the previous report [4].
For the ARSA assay, 0.625 mM 4-MUS was used. Thus, the
final concentration of 4-MUS in an assay solution was 5 mM
for ARSI and 0.5 mM for ARSA. The enzymatic reaction was
performed at 37 °C for 5 h and stopped by adding 1.9 ml of
133  mM  glycine-83  mM  carbonate  buffer  (pH  10.7).
Fluorescence was read at an excitation of 365 nm and an
emission of 445 nm.
Mutation screening: The mutation screening of the ARSI gene
locus  was  performed  using  the  same  genome  DNA  sets
TABLE 3. PRIMERS FOR CONSTRUCTION OF EXPRESSION VECTORS.
Gene Primer name Sequence (5′-3′)
ARSA-FLAG 370fw-HindIII taaagcttATGTCCATGGGGGCACCGCG
1896rv-KpnI atggtaccGGCATGGGGATCTGGGCAAT
ARSI-FLAG 580fw-EcoRI ctgaattccaccATGCACACCCTCACTGGCTTC
2287rv-BglII ttagatctccGATCCGTTGGGACATTAGCCT
ARSICΔ46-FLAG 580fw-EcoRI ctgaattccaccATGCACACCCTCACTGGCTTC
2211rv-BglII ttagatctGCCCAGGGCCCCCAAGCA
SUMF1-FLAG 15fw-HindIII tcaagcttCGCGGGACAACATGGCTG
1147rv-KpnI ttggtaccGTCCATGGTGGGCAGGCG
SUMF1-myc 20fw-HindIII ataagcttGACAACATGGCTGCGCCC
1147rv-SacII ttccgcggGTCCATGGTGGGCAGGCG
S1ARSI-myc SUMF1fw CGCCTGCCCACCATGGAC
SUMF1rv-XbaI cttctagaCCCTGCCGCTCCACACAG
ARSIfw-XbaI cctctagaCCTCCCCACATCATCTTCA
ARSIrv-SacII atccgcggGATCCGTTGGGACATTAGCCT
S1ARSICΔ46-FLAG SUMF1–20fw-EcoRI atgaattcGACAACATGGCTGCGCCC
ARSI-2211rv-BglII ttagatctGCCCAGGGCCCCCAAGCA
In the "Sequence" column, uppercase letters represent a cDNA sequence and lowercase letters denote a restriction site. Bold
underlining  indicates an initiation codon. The coding region of each gene was amplified using the primer set. The amplified
product was cut with the corresponding restriction enzyme and was then cloned into pFLAG-CMV-5 or pcDNA3.1/myc-His.
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485isolated from 68 unrelated RP patients as those used for the
mutation screening of rhodopsin gene [17]. The study was
approved by the Human Genome-Ethics Committee of the
National Rehabilitation Center for Persons with Disabilities
and was performed in accordance with the Declaration of
Helsinki. Informed consent was obtained from all subjects
involved in this study.
Genomic DNA was isolated from venous blood using a
Puregene®  DNA  purification  kit  (Gentra  Systems,
Minneapolis,  MN).  A  sample  for  DNA  sequencing  was
prepared by PCR using genomic DNA as a template. The
genomic sequence of the ARSI locus (NT_029289.10) was
retrieved from the NCBI database (Build 36.3). Nucleotide A
of the initiation codon of ARSI was defined as Position 1. The
primer sequences for PCR amplification are listed in Table 4.
The  first  PCR  amplification  was  performed  to  obtain  an
amplicon spanning an entire region of the ARSI locus. Then
200 ng of genomic DNA were amplified with TaKaRa Ex
TaqTM polymerase (Takara Bio) in a 50 μl reaction volume for
30  cycles  under  conditions  of  heating  for  30  s  at  96  °C,
annealing for 30 s at 63 °C, and extension for 4 min at 72 °C.
The second PCR amplification using the amplicon A1 as a
template  produced  three  amplicons  (A2,  A3,  A4).  PCR
products were sequenced bidirectionally, using the primers
listed in Table 1.
RESULTS
Cloning of arylsulfatase I cDNA: By the 5′-end single-pass
sequencing analysis of 24,000 clones isolated from ARPE-19
cDNA libraries, we identified one full-length cDNA clone
each for ARSI and SUMF1 [16]. To obtain ARSA and ARSB
cDNA clones, PCR-based screening was performed against
the  remaining  69,504  clones.  As  a  result,  one  full-length
cDNA clone was identified for ARSA, but not for ARSB. Table
5 shows the size of the isolated full-length cDNA clones, the
size of the protein encoded by these cDNAs, and the length of
the  5′  untranslated  region  (UTR)  and  3′  UTR  with  the
corresponding RefSeq data. Every clone had an additional G
at the 5′ end, which is a characteristic of a full-length cDNA
clone prepared using the vector-capping method [15]. The
length of the 5′ UTR was somewhat different between the
obtained  cDNA  and  RefSeq  due  to  the  diversity  of  the
transcriptional start sites. The coding region of the ARSI and
ARSA  cDNAs  had  the  same  nucleotide  sequence  as  the
corresponding  RefSeq,  but  there  was  one  synonymous
substitution, Thr(ACT)372Thr(ACC), in the coding region of
the  SUMF1  cDNA  clone.  Based  on  comparison  with  the
genome sequence, two sequence variations were found at the
3′ UTR of the ARSI cDNA clone, and ten sequence variations
were found at the 3′ UTR of the SUMF1 cDNA clone.
Expression profile of arylsulfatase I mRNA: The expression
profiles of ARSI, ARSA, ARSB, and SUMF1 were obtained
based on the UniGene EST count data as shown in Figure 1A.
ARSA was expressed in 38 of 45 tissues and its EST count was
highest among the four genes. In contrast, ARSI was expressed
in  only  13  tissues,  and  the  EST  count  was  one  order  of
magnitude lower than that of ARSA. To obtain a more accurate
TABLE 4. POLYMERASE CHAIN REACTION PRIMERS USED FOR AMPLIFYING THE ARYLSULFATASE I GENE LOCUS.
Amplicon Primer Position Sequence (5′->3′)
A1 A1F -232 CCCGGTTGGACTAGGAAATGATGGGCTT
A1R 6442 GTCCTGGTACTGGTTTGGGGGCTCTTCACAG
A2 A1F -232 CCCGGTTGGACTAGGAAATGATGGGCTT
A2R 2062 CACTAACCTGCACCACCACCCC
A3 A3F 1588 GGCGAGGCAGCAGGATTACAGG
A3R 5002 CCGCACGCCACCTTCCCAATAA
A4 A4F 4525 CACCTTCCTGGGCTCGCTCACG
A1R 6442 GTCCTGGTACTGGTTTGGGGGCTCTTCACAG
Position 1 corresponds to the nucleotide A of the initiation codon of the ARSI gene.
TABLE 5. FULL-LENGTH CDNA CLONES ISOLATED IN THIS STUDY.
Gene GeneID HP number Clone name Accession number mRNA
(bp)
5′ UTR
(bp)
Protein
(aa)
3′ UTR
(bp)
ARSI 340075 HP10847 ARe01G09 AB448735 3159 580 569 869
RefSeq NM_001012301.2 3167 589 569 868
ARSA 607574 HP07238 ARiS019G20 AB448736 2014 374 507 116
RefSeq NM_000487.4 2053 406 507 123
SUMF1 285362 HP06735 ARiS078E09 AB448737 2127 8 374 994
RefSeq NM_182760.2 2148 25 374 998
Each cDNA clone was fully sequenced using a primer walking method. The sequence data was available from GenBank/EMBL/
DDBJ under the corresponding accession number.
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486expression profile for ARSI, we rechecked the EST database
with BLAST. Hit sequences were clustered considering the
presence of 5′-end and 3′-end ESTs derived from the same
clone. As a result, the tissues expressing ARSI were, in order
from  the  top,  placenta  (7  ESTs),  retinoic  acid-treated
embryonic stem cell (6), retinoic acid-treated NT2 embryonic
carcinoma cell line (3), colon tumor (3), fetal eyes (3), and
lens (3), suggesting that ARSI is preferentially expressed in
placenta, embryonic cell, and eye. These results are consistent
with the previous report based on northern blot analysis that
ARSI is detected only in placenta and fetal tissues [6]. It should
be noted that the EST count of ARSI was larger than that of
ARSA or SUMF1 in embryonic cell and eye.
Figure 1B shows the results of RT–PCR performed using
human RPE cell line ARPE-19, human retinoblastoma Y79,
and  other  cell  lines.  The  ARSI  mRNA  was  detected  in
ARPE-19 but not in Y79, suggesting that RPE is one of the
cells preferentially expressing ARSI. NT2/D1 and HT-1080
showed a faint band.
Subcellular localization of arylsulfatase I: To examine the
subcellular  localization  of  ARSI,  we  transfected  the
expression vector of FLAG-tagged ARSI (ARSI-FLAG) into
ARPE-19 cells. The ER was detected using anti-PDI antibody,
and  the  lysosomes  were  detected  using  anti-cathepsin  D
antibody. Indirect immunofluorescence staining and confocal
microscopy showed that ARSI-FLAG was localized in the
intracellular granular structures and colocalized with the ER
(Figure 2A) but not with the lysosomes (Figure 2B). ARSI-
FLAG also was colocalized with the coexpressed SUMF1-
myc, and the distribution pattern of ARSI-FLAG was similar
regardless  of  the  coexpression  of  SUMF1-myc  (data  not
shown). ARSI possesses additional 47- and 45-amino acid
residues at the carboxyl-terminal compared to ARSA and
ARSB, respectively. The deletion of the C-terminal residues
did not affect the distribution pattern of the expression product
(data not shown).
Production of FLAG-tagged proteins: To characterize the
expression products of SUMF1 and ARSs, we constructed the
expression vectors of FLAG-tagged genes (SUMF1-FLAG,
ARSA-FLAG, ARSI-FLAG, and ARSI-C93S-FLAG) as shown
in  Figure  2C  (constructs  1–4).  ARSI-C93S-FLAG  was
constructed as a mutant derivative by replacing a putative
active site of ARSI, Cys at position 93, with Ser. Each fraction
of the cultured cells transfected by these expression vectors
was analyzed by SDS–PAGE and western blotting. As the
production levels of SUMF1-FLAG were larger than those of
the ARSs, a smaller amount of expression vector for SUMF1-
FLAG was used for transfection. As shown in Figure 2D,
Figure  1.  Expression  profile  of
arylsulfatase-related genes. A: Thirteen
tissues expressing ARSI were described
based  on  the  expressed  sequence  tag
(EST) counts of UniGene database. The
total EST counts and the total number of
tissues expressing each gene are listed
in  the  inset  table.  B:  Arylsulfatase-
related gene expressions in human cell
lines were analyzed using RT–PCR. A
eukaryotic elongation factor 1 alpha 1
(EEF1A1) gene was used as an internal
control.
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487ARSA-FLAG  and  SUMF1-FLAG  were  detected  in  all
fractions, including the medium, but ARSI-FLAG was visible
only in the insoluble fraction under these conditions. The size
of ARSA-FLAG was 63.5 kDa, which is in agreement with
the  size  estimated  from  the  sum  of  glycosylated  ARSA
(62 kDa) [18] and the FLAG tag (1.2 kDa). The smaller three
bands seemed to be degradation products. SUMF1-FLAG was
observed as two bands of 36 kDa and 39 kDa in the cellular
extracts, and two bands of 36 kDa and 41 kDa in the medium.
The size of ARSI-FLAG detected in the insoluble fraction was
72 kDa, which was larger than the calculated value 63.8 kDa
based on its amino acid sequence. This result suggests that the
product  was  glycosylated  through  four  potential  N-
glycosylation sites (Asn276, Asn288, Asn466, and Asn496)
in  ARSI.  The  size  and  production  levels  of  ARSI-C93S-
FLAG were the same as those of wild-type ARSI-FLAG.
Production of ARSI derivatives: As wild-type ARSI could not
give a large amount of expression products, we designed two
derivatives,  ARSICΔ46-FLAG  and  S1ARSICΔ46-FLAG
(Figure  2C,  constructs  5  and  6).  ARSICΔ46-FLAG  was
constructed by deleting the C-terminal 46 amino acids that
lacks  in  ARSA  and  ARSB.  S1ARSICΔ46-FLAG  was
prepared based on ARSICΔ46-FLAG by replacing the signal
sequence of ARSI with that of SUMF1, because the signal
peptide  of  SUMF1  was  likely  to  be  involved  in  high
production levels of SUMF1-FLAG. ARSICΔ46-FLAG and
S1ARSICΔ46-FLAG were detected in the insoluble factions
at positions of lower molecular mass, as expected from the
decrease caused by the deletion or replacement of amino acid
residues. ARSICΔ46-FLAG gave a weak band in the cell
extract. The production levels of ARSI-FLAG were one-third
those  of  ARSA-FLAG  in  the  insoluble  fraction.  The  C-
Figure  2.  Transient  expression  of
arylsulfatase-related  genes.  A  and  B:
Endogenous PDI (ER marker, A) and
cathepsin D (lysosome marker, B) were
immunostained.  ARPE-19  cells  were
transfected with 6 μg of the expression
vector ARSI-FLAG. Scale bars, 10 μm.
C:  The  structures  of  FLAG-tagged
protein constructs were depicted. The
colored box at the N-terminal represents
a  signal  sequence.  The  active  site  of
ARSI, Cys (C), was replaced by Ser (S)
in a mutant derivative. The size of each
secreted  mature  protein  was
represented. D: The expression products
were  analyzed  with  western  blot.
ARPE-19 cells were transfected with 1
μg SUMF1-FLAG, 5 μg ARSA-FLAG,
or 8 μg ARSI derivatives, and cultured
in serum-containing media for 22 h and
then in serum-free media for 9 h. Loaded
were  20%  of  the  total  sample  for
insoluble fraction, 10% for cell extract,
and 25% for medium. The lane number
corresponds to the construct number of
the FLAG-tagged protein described in
C.
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488terminal deletion increased the production levels to twice
those of ARSI-FLAG. However, the replacement of the N-
terminal signal sequence of ARSICΔ46 by that of SUMF1 did
not induce a significant increase in the production levels.
Arylsulfatase  activity  of  expression  products  in  cellular
fractions: As the production of ARSI-FLAG was confirmed,
the ARS activity was measured using the cellular extracts.
Although we did not observe any band in the cellular extracts
under the aforedescribed culture conditions, we could detect
a weak but clear band of ARSI-FLAG by changing the culture
conditions as shown in Figure 3A. As SUMF1 is known to
activate  ARSs,  SUMF1-FLAG  was  coexpressed  for
supplementation  of  SUMF1.  Figure  3A  shows  that  every
expression  product  was  observed  in  the  cellular  extracts.
Although the ratio of transfected expression vectors (ARSA-
FLAG,  ARSI-FLAG,  and  SUMF1-FLAG)  was  5:8:1,  the
production levels of ARSI-FLAG were significantly low.
First, the activity of ARSA-FLAG was measured using
4-MUS as a substrate. The cellular extract of ARSA-FLAG-
expressed  cells  showed  markedly  high  ARS  activity
compared  with  the  endogenous  activity  (Figure  3B).
Coexpression of SUMF1-FLAG increased the ARS activity,
indicating that some of the overproduced ARSA-FLAG was
activated  by  endogenous  SUMF1  and  that  the  remaining
excess ARSA-FLAG was further activated by the coexpressed
SUMF1-FLAG product.
The ARS activity of the cellular extract of ARSI-FLAG-
expressed cells was as low as the endogenous activity (Figure
3C). As shown in Figure 3B, the endogenous ARS activity
was >10-fold lower than that of ARSA-FLAG-expressed cells.
Thus, a 10-fold higher substrate concentration, 5 mM, was
used to detect a small difference in activity. The optimum pH
of the endogenous ARS activity was around 6 (Figure 3D).
Unexpectedly,  the  expression  of  ARSI-FLAG  caused  a
decrease in endogenous ARS activity. The coexpression with
SUMF1-FLAG  resulted  in  a  recovery  of  and  even  slight
increases  in  activity  at  neutral  pH  range.  In  contrast,  the
expression  of  ARSI-C93S-FLAG  did  not  induce  such  a
decrease in endogenous ARS activity, and coexpression with
SUMF1-FLAG  did  not  change  this  activity.  These  results
suggest  that  the  overexpressed  ARSI-FLAG  in  the  cell
extracts  had  no  ARS  activity  and  caused  the  decrease  in
endogenous  ARS  activity  by  a  mechanism  related  to  the
activation of ARSI with SUMF1.
Arylsulfatase activity of expression products secreted into
media:  The  overexpression  product  of  ARSA-FLAG  or
Figure  3.  Arylsulfatase  activity  of
cellular  extracts.  A:  Cellular  extracts
were  analyzed  with  western  blot.
Transfected  were  5  μg  ARSA-FLAG
(lanes 1 and 2), 8 μg ARSI-FLAG (lanes
3 and 4), and 1 μg SUMF1-FLAG (lanes
2  and  4)  into  ARPE-19  cells  .The
transfected cells were cultured in media
for  72  h.  The  amount  of  the  loaded
sample was 10 μg protein for ARSA and
12.5 μg protein for ARSI. B: The ARS
activity of ARSA-FLAG was measured
at pH 5.0 using 0.5 mM 4-MUS as a
substrate. C: The ARS activity of ARSI-
FLAG was measured at pH 5.6, using 5
mM 4-MUS as a substrate. The activity
was calculated as the value per mg of
cellular protein in each fraction. D: The
pH dependence of ARS activities was
shown. The ARS activities in B, C, and
D give the means of three independent
experiments.  Bars  indicate  standard
deviations.  The  error  bars  in  B  were
omitted  because  the  differences
between samples were obvious.
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489SUMF1-FLAG was secreted into the medium as shown in
Figure 2D. ARSA-FLAG was introduced into ARPE-19 cells
with  or  without  SUMF1-FLAG,  and  the  products  in  the
cellular fractions and media were analyzed by SDS–PAGE
and  western  blotting.  Interestingly,  the  band  of  SUMF1-
FLAG in the medium almost disappeared when there was
coexpression with ARSA-FLAG (Figure 4A). The high activity
of secreted ARSA-FLAG was detected at acidic pH, and the
coexpression with SUMF1-FLAG drastically increased the
ARSA activity (Figure 4B). These results suggest that the
endogenous  SUMF1  is  not  enough  to  activate  the
overproduced ARSA-FLAG.
The band of ARSI-FLAG was detected in the cellular
fraction, but not in the concentrated medium (Figure 4C).
During the concentration process of the conditioned medium,
the degradation of the secreted ARSI may occur. When the
medium  was  treated  with  TCA  without  the  concentration
process,  the  precipitate  showed  the  band  of  ARSI-FLAG
(Figure 4D), suggesting that ARSI-FLAG was secreted into
the medium and that its amount in the concentrated medium
was too small to be detected. As in the case of ARSA-FLAG,
the band of SUMF1-FLAG in the medium disappeared when
it was coexpressed with ARSI-FLAG or ARSI-C93S-FLAG. It
should  be  noted  that  the  band  of  SUMF1  in  the  cellular
fraction also was reduced by coexpression with ARSI-FLAG.
The ARS activity of the conditioned medium of ARSI-
FLAG-expressed cells was as low as that of the endogenous
secreted ARS at every pH (Figures 4E,F). As shown in Figure
Figure  4.  Arylsulfatase  activity  of
media.  A:  Arylsulfatase  A  (ARSA)
products  were  analyzed  with  western
blot.  ARPE-19  cells  were  transfected
with  5  μg  ARSA-FLAG  and  1  μg
SUMF1-FLAG, and cultured in serum-
containing media for 2 h and then in
serum-free media for 22 h. Loaded was
12.5% of the total sample. B: The ARS
activity of ARSA-FLAG was measured
using  0.4%  of  the  total  medium.  C:
Arylsulfatase  I  (ARSI)  products  were
analyzed with western blot. Transfected
were  8  μg  ARSI-FLAG,  8  μg  ARSI-
C93S-FLAG, and 1 μg SUMF1-FLAG
into  ARPE-19  cells.  D:  The
trichloroacetic  acid  (TCA)-induced
precipitate of the medium was analyzed
with western blot. E: The ARS activity
of  ARSI-FLAG  was  measured  using
20% of the total medium. F: The pH
dependence  of  ARS  activities  was
shown. The ARS activities in B, E, and
F give the means of three independent
experiments.  Bars  indicate  standard
deviations.
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4904B, the endogenous ARS activity was approximately 100 fold
lower  than  the  medium  ARS  activity  of  ARSA-FLAG-
expressed cells. The optimum pH of endogenous ARS activity
was  acidic,  suggesting  that  this  activity  may  result  from
secreted lysosomal ARSs such as ARSA [19]. The difference
in optimum pH between the endogenous ARS activities of the
cell extracts (Figure 3D) and the medium (Figure 4F) may
reflect the difference in endogenous ARS species. Only when
ARSI-FLAG and SUMF1-FLAG were coexpressed did the
media show significant ARS activity—2.5 fold higher than
the endogenous activity at pH 7.4 (Figure 4E). The ARS
activity  of  the  secreted  ARSI-FLAG  was  estimated  by
subtracting the endogenous activity (Figure 4F). The optimum
pH of the secreted ARSI-FLAG seemed to be around pH 7.
However,  ARSI-C93S-FLAG  did  not  show  any  activity.
These  results  indicate  that  ARSI  is  activated  by  SUMF1
through modification of Cys93 into FGly, is secreted into the
medium, and shows ARS activity at neutral pH.
Sequence variation of arylsulfatase I gene locus: Patients with
some forms of MPS that were caused by the mutation of
ARSs  are  known  to  show  symptoms  characteristic  of  RP
[8-13]. Thus, ARSI preferentially expressed in RPE can be a
candidate  gene  responsible  for  RP.  We  have  previously
performed mutation screening of rhodopsin gene in Japanese
RP patients. The same genome DNA sets isolated from 68 RP
patients were used for mutation screening of the ARSI gene
locus. The ARSI gene is located at chromosome 5q33.1 and is
composed of two exons spanning a 6.4 kb region. The entire
region was amplified by PCR and fully sequenced. Table 6
shows a total of 25 sequence variations, including ones found
in  this  study  and  ones  registered  in  the  single  nucleotide
polymorphism database (dbSNP). Our samples contained 14
single  nucleotide  substitutions,  seven  of  which  were  not
registered in dbSNP. Out of seven novel single nucleotide
substitutions, four were rare substitutions, and three (SV10,
SV22,  and  SV25)  were  SNPs  with  >8%  minor  allele
frequency (MAF). However, 11 substitutions registered in
dbSNP were not found in our samples. Two synonymous
substitutions (SV19 and SV22) were found in the coding
region, but there was no nucleotide sequence variation causing
an amino acid substitution. The analysis of the control subjects
was not performed because no candidate mutation was found.
DISCUSSION
This study arose from the discovery of the ARSI cDNA clone
during the comprehensive analysis of genes expressed in the
RPE cell line ARPE-19 [15,16]. Expression profile analysis
using several cell lines showed that ARSI is preferentially
TABLE 6. NUCLEOTIDE SEQUENCE VARIATIONS OBSERVED IN THE ARYLSULFATASE I GENE LOCUS.
Marker
name
SNP
name
Region Amplicon Position Alleles major/minor dbSNP ID Minor allele
frequency (%)
SV01 SNP01 Exon 1 A2 −272 C/T rs968431 30.15
SV02 - Intron A2 503 T/G - 0.74
SV03 SNP02 Intron A2, A3 1128 A/T rs10463232 2.21
SV04 - Intron A3 1283 C/T rs930209 0.00
SV05 - Intron A3 1314 G/A rs7445044 0.00
SV06 - Intron A3 1328 G/T - 0.74
SV07 SNP03 Intron A3 1345 C/T rs930210 12.50
SV08 - Intron A3 1440 G/A rs11956540 0.00
SV09 - Intron A3 1678 C/T rs4286653 0.00
SV10 SNP04 Intron A3 1733 T/C - 12.50
SV11 - Intron A3 1769 G/A rs11956439 0.00
SV12 SNP05 Intron A3 2293 C/A rs12522210 9.56
SV13 - Intron A3 2318 A/- rs34043807 0.00
SV14 SNP06 Intron A3 2674 G/A rs9324643 13.97
SV15 - Intron A3 2991–2995 ACGAG/- - 0.74
SV16 - Intron A3 3534 C/T rs11744744 0.00
SV17 SNP07 Intron A3 3612 C/T rs6579786 9.56
SV18 SNP08 Intron A3 3641 C/T rs6579785 22.06
SV19 - Exon 2 A3 4005 C/T (Gly185Gly) - 0.74
SV20 - Exon 2 A3, A4 4086 C/T (Tyr212Tyr) rs6579784 0.00
SV21 - Exon 2 A4 4225–4226 -/C (frame shift) rs34775469 0.00
SV22 SNP09 Exon 2 A4 4344 T/C (Asn298Asn) - 8.09
SV23 - Exon 2 A4 5466–5467 -/C rs34570494 0.00
SV24 - Exon 2 A4 5640 C/A rs17111118 0.00
SV25 SNP10 Exon 2 A4 5644 C/T - 11.76
Position 1 corresponds to the nucleotide A of the initiation codon of the ARSI gene. Sixty-eight unrelated patients with retinitis
pigmentosa were subjected to mutation screening. The sequence variations include ones found in this study and ones registered
in the single nucleotide polymorphism database (dbSNP). The sequence variation with >1% minor allele frequency was defined
as SNP.
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491expressed in ARPE-19 but not in Y79. As the mutation of
ARSs has been known to cause lysosomal storage diseases
accompanying  RP-like  symptoms,  we  thought  that  ARSI
preferentially expressed in RPE could be a candidate gene
responsible for RP. We have previously performed mutation
screening of the RHO gene locus using the genome DNA of
68 RP patients [17]. The same samples were used for mutation
screening of the ARSI gene locus. Unfortunately, we found no
missense  or  nonsense  mutations  but  two  synonymous
substitutions, suggesting that ARSI is not a causative gene for
the patients examined in this study. The sequence variation
registered in dbSNP, SV21 (rs34775469, Table 6), is located
in the coding region and causes a frame shift by insertion of
one nucleotide. This shift is expected to produce C-terminal
truncated ARSI. However, there is no available information
as to whether subjects possessing this variation suffer from
visual impairment.
During our mutation screening of the ARSI gene locus,
the identification of ARSI as ARSB paralog [5] and the cloning
and expression of the ARSI cDNA [6] were reported. Obaya
examined the expression of ARSI-FLAG in HeLa cells and
observed  the  band  of  ARSI-FLAG  by  SDS–PAGE  and
western  blotting,  but  failed  to  show  clear  subcellular
localization and its ARS activity [6]. To characterize the ARSI
protein,  we  tried  to  overexpress  the  ARSI  cDNA  and  to
determine the ARS activity of ARSI. As ARSs are known to
require activation by SUMF1 in the ER, we obtained full-
length cDNA clones encoding SUMF1 and ARSA from the
ARPE-19 cDNA library. Using these clones, we examined the
transient expression of these cDNAs in ARPE-19 cells. ARSI-
FLAG was shown to colocalize with the ER marker but not
with the lysosomal marker, suggesting that the overproduced
ARSI exists in the ER. SDS–PAGE analysis showed that the
band of the expression product of ARSI-FLAG was observed
in the cellular extracts and the insoluble cellular fraction, but
that their production levels were lower than those of ARSA-
FLAG or SUMF1-FLAG. Most of the overproduced ARSA-
FLAG  and  SUMF1-FLAG  were  secreted  into  the  media,
whereas a visible band of ARSI-FLAG could not be observed
in the concentrated media showing the ARS activity. The only
difference among these expression vectors is the nucleotide
sequence of the coding region. The replacement of the signal
sequence by that of SUMF1 and the deletion of the C-terminal
extension  little  improved  the  production  levels  of  ARSI-
FLAG. One possible explanation for the low production of
ARSI is that ARSI is unstable and easily degraded in the ER
or extracellular space. To obtain a large amount of ARSI
protein, further investigation is required.
During expression analyses of ARS-related genes, we
found  interesting  phenomena  indicating  that  most  of  the
SUMF1-FLAG  was  secreted  into  medium  by  the  sole
expression of SUMF1-FLAG, but not by coexpression with
ARSA-FLAG  or  ARSI-FLAG.  There  are  three  possible
explanations  for  this  phenomenon:  1)  the  decrease  in
expression levels due to competition with the expression of
ARSs; 2) the intracellular retention of the product; and 3) the
degradation of the product. As the production levels of ARSA-
FLAG  did  not  change,  the  first  explanation  may  not  be
appropriate. As the amount of the intracellular product did not
change, or rather decreased, the possibility of the intracellular
retention also may be negligible. In relation to this, we should
note the differences between the intracellular (39 kDa) and
secreted forms (41 kDa, 36 kDa, and 33 kDa) of SUMF1-
FLAG (Figures 4A,C). Similar results have been reported
regarding the difference between intra- and extracellular His-
tagged  SUMF1  [20],  with  the  size  heterogeneity  being
explained by the differences in glycosylation and N-terminal
truncation.  Consequently,  our  third  explanation  is  most
plausible.  It  has  been  reported  that  ARS  activities  are
regulated by the interaction with SUMF1 and SUMF2 [21].
The present results led us to suppose that SUMF1 is degraded
after  interacting  with  ARSs.  Further  investigation  of  the
regulation mechanism of ARSs by SUMF1 is necessary to
confirm the present hypothesis.
The ARS activity of ARSI-FLAG could not be detected
in the cellular extract that showed a visible band of expression
product, but the conditioned media of cells coexpressed with
SUMF1-FLAG showed significant ARS activity, despite the
absence of the visible band of ARSI-FLAG. Furthermore, the
overproduction of ARSI-FLAG, but not ARSI-C93S-FLAG,
caused the decrease in endogenous ARS activity in the cell
extracts. This decrease was recovered by coexpression with
SUMF1-FLAG. All these phenomena could be explained by
assuming the following: 1) ARSI is a secreted protein; 2) the
secreted ARSI is rapidly degraded in the ER or medium; 3)
when ARSI is overproduced, a part of overproduced product
is  retained  in  the  ER  as  a  denatured  form;  and  4)
overproduction of ARSI causes degradation of SUMF1. The
activity of ARSI-FLAG in the medium may result from a low
amount of ARSI-FLAG escaping degradation. Expectedly,
the  TCA-precipitated  product  of  the  conditioned  medium
gave the band of ARSI-FLAG that could not be detected in
the concentrated medium. The decrease in endogenous ARS
activity in the cell extract may be caused by degradation of
endogenous SUMF1 due to overproduction of ARSI-FLAG,
and the endogenous ARS of expression vectors-free cells may
bear the remaining activity. Consequently, the key issue to be
solved is the degradation mechanism of ARSI and SUMF1.
The conditioned media of ARSI-C93S-FLAG-expressed
cells  coexpressed  with  SUMF1-FLAG  showed  no  ARS
activity. This result confirms that the active site of ARSI is
Cys93 and that it is activated by SUMF1 as well as other
ARSs. The low activity in the present study may be due to the
rapid degradation of the secreted ARSI-FLAG. The optimum
pH of ARSI-FLAG secreted into the medium was around
neutral range, while lysosomal ARSs, such as ARSA and
ARSB, show the highest activity at acidic pH. These results
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492strongly suggest that ARSI is secreted and functions in the
extracellular environment.
The  characteristics  of  ARSI  revealed  by  the  present
investigation,  the  possibility  of  extracellular  ARS
preferentially expressed in embryonic tissues, are a reminder
that extracellular matrix sulfatases have been shown to be
involved  in  signal  transduction  during  embryonic
development  [22].  For  example,  QSulf1,  which  is  a  cell-
surface sulfatase found in quail embryos, has been noted to be
active in Wnt signaling and embryonic development [23]. Its
human orthologs, HSulf1 and HSulf2, have been isolated and
confirmed  to  be  extracellular  heparin-degrading
endosulfatases [24]. These reports and our present findings
led  us  to  suppose  that  ARSI  also  functions  during
developmental stages, whereas the meaning of the preferential
expression in the eye is unknown. To understand the function
of ARSI, it is necessary to determine its physiologic substrate.
From a structural perspective, the C-terminal extended amino
acid residues of ARSI may play an important role in substrate
recognition.  The  HSulf  sulfatases  and  HGlcN6S,  which
catalyze the hydrolysis of glucosamine 6S residues, contain
the  C-terminal  stretch  of  amino  acids  that  exhibit  high
homology  with  a  region  of  the  GlcNAc  transferase  from
Arabidopsis  thaliana,  suggesting  that  this  region  may  be
involved in substrate recognition [24]. The search for a target
molecule interacting with the C-terminal residues of ARSI
should provide information regarding its true substrate.
In conclusion, we succeeded for the first time in detecting
the  ARS  activity  of  ARSI  and  found  that  ARSI  may  be
secreted  and  function  in  the  extracellular  space.  Further
investigation will shed light on the role of ARSI in the function
of RPE cells. ARSI seems not to be a lysosomal ARS, and
thus to not be a causative gene in lysosomal storage disorders.
However, ARSI preferentially expressed in the eye would still
be a candidate gene causing inherited eye diseases for future
mutation screening.
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